Poliomyelitis - Pipeline Review, H2 2017

  • ID: 4446857
  • Report
  • 68 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Biological Mimetics Inc
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson
  • Kaketsuken
  • MORE
Poliomyelitis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H2 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 2, 1, 1 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Biological Mimetics Inc
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson
  • Kaketsuken
  • MORE
Introduction

Poliomyelitis - Overview

Poliomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Poliomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Poliomyelitis - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Biological Mimetics Inc

GlaxoSmithKline Plc

Grifols SA

Johnson & Johnson

Kaketsuken

LG Chem Ltd

Nanolek

Panacea Biotec Ltd

Sanofi

Sanofi Pasteur SA

Sentinext Therapeutics Sdn Bhd

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Takeda Pharmaceutical Co Ltd

Poliomyelitis - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTaP-IPV-HB-PRPT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPVGVI-3000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-2348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio (virus like particle, bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poliomyelitis - Dormant Projects

Poliomyelitis - Discontinued Products

Poliomyelitis - Product Development Milestones

Featured News & Press Releases

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

May 11, 2011: Sanofi Pasteur Launches Pentaxim In China

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Poliomyelitis, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2

Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H2

Poliomyelitis - Pipeline by Biological E Ltd, H2

Poliomyelitis - Pipeline by Biological Mimetics Inc, H2

Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H2

Poliomyelitis - Pipeline by Grifols SA, H2

Poliomyelitis - Pipeline by Johnson & Johnson, H2

Poliomyelitis - Pipeline by Kaketsuken, H2

Poliomyelitis - Pipeline by LG Chem Ltd, H2

Poliomyelitis - Pipeline by Nanolek, H2

Poliomyelitis - Pipeline by Panacea Biotec Ltd, H2

Poliomyelitis - Pipeline by Sanofi, H2

Poliomyelitis - Pipeline by Sanofi Pasteur SA, H2

Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H2

Poliomyelitis - Pipeline by Serum Institute of India Ltd, H2

Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H2

Poliomyelitis - Pipeline by Takeda Pharmaceutical Co Ltd, H2

Poliomyelitis - Dormant Projects, H2

Poliomyelitis - Discontinued Products, H2

List of Figures

Number of Products under Development for Poliomyelitis, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Biological Mimetics Inc
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson
  • Kaketsuken
  • LG Chem Ltd
  • Nanolek
  • Panacea Biotec Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll